Boston Scientific Gives Up On Lotus Edge TAVR
Executive Summary
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
You may also be interested in...
Cardio Catch-Up: Boston Scientific Pushes US TAVR Timeline Again
Boston Scientific's plan to launch the Acurate neo2 TAVR system in the US this year depended on earning an FDA approval based on interim results from the ACURATE IDE trial. The company is optimistic the full data set will support approval after they are announced later this year.
TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
Abbott Becomes Third US TAVR Competitor With Portico Approval
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.